Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Arrowhead Presents New Clinical Data on Cardiometabolic Pipeline at AHA 2020

Abstract:
- ARO-APOC3 achieved triglyceride reductions of 74-92%

- ARO-ANG3 achieved triglyceride reductions of 29-75% and LCL-C reductions of 29-35%

- Company to host upcoming KOL webinars on ARO-APOC3 and ARO-ANG3

Arrowhead Presents New Clinical Data on Cardiometabolic Pipeline at AHA 2020

Pasadena. CA | Posted on November 13th, 2020

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced positive clinical data from multiple product candidates in its cardiometabolic pipeline at the American Heart Association (AHA) Scientific Sessions 2020.

Javier San Martin, M.D., chief medical officer at Arrowhead, said: “The data presented at AHA on our cardiometabolic pipeline continue to show strong and consistent response across a range of lipid parameters. There remains significant residual cardiovascular risk despite recent scientific advances, and we believe that our cardiometabolic pipeline has the ability to target new therapeutic targets and address multiple lipid parameters associated with increased cardiovascular risk.”

Copies of the following presentations may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website:

Title: Pharmacodynamic effect of ARO-ANG3, an investigational RNA interference therapeutic targeting hepatic angiopoietin-like protein 3, in patients with hypercholesterolemia
Authors: Gerald F. Watts, et al.
Session: Advances in Understanding and Treatment of Dyslipidemia and New Therapies for CVD

Title: Pharmacodynamic effect of ARO-APOC3, an investigational hepatocyte-targeted RNA interference therapeutic targeting apolipoprotein C3, in patients with hypertriglyceridemia and multifactorial chylomicronemia
Authors: Christie Ballantyne, presenting on behalf of Peter Clifton, et al.
Session: Advances in Understanding and Treatment of Dyslipidemia and New Therapies for CVD

Title: Safety, Tolerability and Efficacy of Single-Dose AMG 890, a Novel siRNA Targeting Lp(a), in Healthy Subjects and Subjects with Elevated Lp(a)
Authors: Michael J. Koren, et al.
Session: Advances in Understanding and Treatment of Dyslipidemia and New Therapies for CVD

Arrowhead will also host two key opinion leader (KOL) webinars on November 18, and November 19, 2020 to discuss data from, and the company’s future plans for, its two investigational cardiometabolic candidates, ARO-APOC3 and ARO-ANG3. The webinars may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400


Investors:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Media:
LifeSci Communications, LLC
Josephine Belluardo, Ph.D.
646-751-4361

www.lifescicommunications.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Intelligent optical chip to improve telecommunications: An INRS team uses autonomous learning approaches for optical waveform generators to boost optical signal processing functionalities for current and future telecom applications October 15th, 2021

Using quantum Parrondo’s random walks for encryption: Asst Prof Kang Hao Cheong and his research team from SUTD have set out to apply concepts from quantum Parrondo’s paradox in search of a working protocol for semiclassical encryption October 15th, 2021

Cellular environments shape molecular architecture: Researchers glean a more complete picture of a structure called the nuclear pore complex by studying it directly inside cells October 15th, 2021

How to program DNA robots to poke and prod cell membranes: A discovery of how to build little blocks out of DNA and get them to stick to lipids has implications for biosensing and mRNA vaccines October 15th, 2021

Nanomedicine

Cellular environments shape molecular architecture: Researchers glean a more complete picture of a structure called the nuclear pore complex by studying it directly inside cells October 15th, 2021

How to program DNA robots to poke and prod cell membranes: A discovery of how to build little blocks out of DNA and get them to stick to lipids has implications for biosensing and mRNA vaccines October 15th, 2021

Directly into the brain: A 3D multifunctional and flexible neural interface: Novel design of brain chip implant allows for measuring neuronal activity while simultaneously delivering drugs to the implant site October 1st, 2021

New nano particles suppress resistance to cancer immunotherapy September 17th, 2021

Announcements

Using quantum Parrondo’s random walks for encryption: Asst Prof Kang Hao Cheong and his research team from SUTD have set out to apply concepts from quantum Parrondo’s paradox in search of a working protocol for semiclassical encryption October 15th, 2021

Cellular environments shape molecular architecture: Researchers glean a more complete picture of a structure called the nuclear pore complex by studying it directly inside cells October 15th, 2021

How to program DNA robots to poke and prod cell membranes: A discovery of how to build little blocks out of DNA and get them to stick to lipids has implications for biosensing and mRNA vaccines October 15th, 2021

Molecular Sciences Software Institute receives $15 million grant from National Science Foundation October 15th, 2021

Events/Classes

Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences September 1st, 2021

UVA Engineering researchers join quest to demonstrate photonic systems-on-chip: Future applications include faster, more efficient data centers and next-generation millimeter-wave wireless communication July 30th, 2021

Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress June 25th, 2021

Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress June 24th, 2021

Nanobiotechnology

Cellular environments shape molecular architecture: Researchers glean a more complete picture of a structure called the nuclear pore complex by studying it directly inside cells October 15th, 2021

How to program DNA robots to poke and prod cell membranes: A discovery of how to build little blocks out of DNA and get them to stick to lipids has implications for biosensing and mRNA vaccines October 15th, 2021

New nano particles suppress resistance to cancer immunotherapy September 17th, 2021

Getting to the root of tooth replantation challenges: Researchers from Tokyo Medical and Dental University (TMDU) report a delivery system that promotes healing in tooth replantation in rats September 17th, 2021

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project